These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 28476135)

  • 1. The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.
    Heirali AA; Workentine ML; Acosta N; Poonja A; Storey DG; Somayaji R; Rabin HR; Whelan FJ; Surette MG; Parkins MD
    Microbiome; 2017 May; 5(1):51. PubMed ID: 28476135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome.
    Heirali AA; Acosta N; Storey DG; Workentine ML; Somayaji R; Laforest-Lapointe I; Leung W; Quon BS; Berthiaume Y; Rabin HR; Waddell BJ; Rossi L; Surette MG; Parkins MD
    J Cyst Fibros; 2019 Nov; 18(6):829-837. PubMed ID: 30857926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
    McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
    Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
    Elborn JS; Henig NR
    Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
    Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
    J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough?
    Bos AC; van Holsbeke C; de Backer JW; van Westreenen M; Janssens HM; Vos WG; Tiddens HA
    PLoS One; 2015; 10(3):e0118454. PubMed ID: 25734630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
    Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
    J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: An open-label randomised crossover study (AZTEC-CF).
    Frost F; Young GR; Wright L; Miah N; Smith DL; Winstanley C; Walshaw MJ; Fothergill JL; Nazareth D
    J Cyst Fibros; 2021 Nov; 20(6):994-1002. PubMed ID: 33358119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.
    Pesaturo KA; Horton ER; Belliveau P
    Ann Pharmacother; 2012; 46(7-8):1076-85. PubMed ID: 22764322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
    Retsch-Bogart GZ; Burns JL; Otto KL; Liou TG; McCoy K; Oermann C; Gibson RL;
    Pediatr Pulmonol; 2008 Jan; 43(1):47-58. PubMed ID: 18041081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled aztreonam lysine: an evidence-based review.
    Hutchinson D; Barclay M; Prescott WA; Brown J
    Expert Opin Pharmacother; 2013 Oct; 14(15):2115-24. PubMed ID: 23992352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.
    Assael BM; Pressler T; Bilton D; Fayon M; Fischer R; Chiron R; LaRosa M; Knoop C; McElvaney N; Lewis SA; Bresnik M; Montgomery AB; Oermann CM;
    J Cyst Fibros; 2013 Mar; 12(2):130-40. PubMed ID: 22985692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aztreonam lysine for inhalation solution: in cystic fibrosis.
    Plosker GL
    Drugs; 2010 Oct; 70(14):1843-55. PubMed ID: 20836577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.
    Wainwright CE; Quittner AL; Geller DE; Nakamura C; Wooldridge JL; Gibson RL; Lewis S; Montgomery AB
    J Cyst Fibros; 2011 Jul; 10(4):234-42. PubMed ID: 21441078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
    Retsch-Bogart GZ; Quittner AL; Gibson RL; Oermann CM; McCoy KS; Montgomery AB; Cooper PJ
    Chest; 2009 May; 135(5):1223-1232. PubMed ID: 19420195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2010 Aug; 4(4):435-44. PubMed ID: 20658904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the lung bacteriome in relation to antipseudomonal therapy in children with cystic fibrosis.
    Kramná L; Dřevínek P; Lin J; Kulich M; Cinek O
    Folia Microbiol (Praha); 2018 Mar; 63(2):237-248. PubMed ID: 29127619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.
    Oermann CM; Retsch-Bogart GZ; Quittner AL; Gibson RL; McCoy KS; Montgomery AB; Cooper PJ
    Pediatr Pulmonol; 2010 Nov; 45(11):1121-34. PubMed ID: 20672296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial.
    Tullis DE; Burns JL; Retsch-Bogart GZ; Bresnik M; Henig NR; Lewis SA; Lipuma JJ
    J Cyst Fibros; 2014 May; 13(3):296-305. PubMed ID: 24176390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
    Littlewood KJ; Higashi K; Jansen JP; Capkun-Niggli G; Balp MM; Doering G; Tiddens HA; Angyalosi G
    J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.